SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — Jun 27, 2016
PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: June 27, 2016 · CIK: 0001614744 · Accession: 0001144204-16-109933
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-211477
Letter
Kitov Pharmaceuticals Holdings Ltd.
One Azrieli Center, Round Building
Tel Aviv, Israel 6701101
972-3-6254124
June 27, 2016
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Irene J. Paik
Re: Kitov Pharmaceuticals Ltd.
Registration Statement on Form F-1, originally filed on May 20, 2016,
File No. 333-211477, as amended (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Kitov Pharmaceuticals Holdings Ltd. (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement so that it may become effective at 4:30 p.m., Eastern Time, on June 28, 2016, or as soon thereafter as practicable.
In connection with the Company’s request for acceleration of the effective date of the Registration Statement, the Company acknowledges the following:
· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharmaceuticals Holdings Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Kitov Pharmaceuticals Holdings Ltd.
One Azrieli Center, Round Building
Tel Aviv, Israel 6701101
972-3-6254124
June 27, 2016
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Irene J. Paik
Re: Kitov Pharmaceuticals Ltd.
Registration
Statement on Form F-1, originally filed on May 20, 2016,
File
No. 333-211477, as amended (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461
promulgated under the Securities Act of 1933, as amended, Kitov Pharmaceuticals Holdings Ltd. (the “Company”)
hereby respectfully requests acceleration of the effective date of the Registration Statement so that it may become effective at
4:30 p.m., Eastern Time, on June 28, 2016, or as soon thereafter as practicable.
In connection with
the Company’s request for acceleration of the effective date of the Registration Statement, the Company acknowledges the
following:
· should the Securities and Exchange Commission (the “Commission”) or the
staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any
action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should any member of
the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and
Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharmaceuticals Holdings Ltd.
By:
/s/ Isaac Israel
Name:
Isaac Israel
Title:
Chief Executive Officer
By:
/s/ Simcha Rock
Name:
Simcha Rock
Title:
Chief Financial Officer